Biology-based markers to confirm or aid in the diagnosis or prognosis of chronic GVHD after allogeneic hematopoietic cell transplantation (HCT) or monitor its progression are critically needed to facilitate evaluation of new therapies. Biomarkers have been defined as any characteristic that is objectively measured and evaluated as an indicator of a normal biological or pathogenic process, a pharmacologic response to a therapeutic intervention. Applications of biomarkers in chronic GVHD clinical trials or patient management include: a) diagnosis and 
assessment of chronic GVHD disease activity, including distinguishing irreversible damage from continued disease activity, b) prognostic risk to develop chronic GVHD, and c) prediction of response to therapy. Sample collection for chronic GVHD biomarkers studies should be welldocumented following established quality control guidelines for sample acquisition, processing, preservation and testing, at intervals that are both calendar-and event-driven. The consistent therapeutic treatment of subjects and standardized documentation needed to support biomarker studies are most likely to be provided in prospective clinical trials. To date, no chronic GVHD biomarkers have been qualified for utilization in clinical applications. Since our previous chronic GVHD Biomarkers Working Group report in 2005, an increasing number of chronic GVHD candidate biomarkers are available for further investigation. This paper provides a four-part framework for biomarker investigations: identification, verification, qualification, and application with terminology based on Food and Drug Administration and European Medicines Agency guidelines.
Keywords
Chronic graft-versus-host disease; biomarkers; NIH; consensus
BACKGROUND
Chronic GVHD is one of the most important long-term complications of allogeneic blood and marrow transplantation, resulting in significant morbidity and mortality [1] . Unlike acute GVHD, chronic GVHD is insidious in its onset and the diagnosis can be difficult. Moreover, chronic GVHD is a multifaceted disease that can affect almost all organs and tissues in the body. Thus, the identification and verification of biomarkers for chronic GVHD is more difficult than for acute GVHD. The scoring system proposed by the NIH Consensus Development Project on Criteria for Clinical Trials in chronic GVHD [2] has now been widely adopted by HCT centers. However, clinical characteristics are not fully informative in predicting the severity of the disease, response to therapy, or survival, and are not adequate to distinguish disease activity from irreversible tissue damage during treatment [3] . As an adjunct to clinical and histological criteria, the availability of biomarkers for chronic GVHD could potentially improve the classification of patients into risk groups and thereby refine chronic GVHD diagnosis, estimate the risk of developing chronic GVHD or predict response to therapy.
The pathogenesis of chronic GVHD involves a number of biological mechanisms potentially contributing to its development and evolution. Historically, chronic GVHD was believed to be a chronic continuation of the same effector mechanisms that cause acute GVHD, i.e., donor T cells having specificity for recipient-restricted histocompatibility antigens that produce cytokines. However, differences in the clinical presentations of acute and chronic GVHD suggest that the effector mechanisms might differ. Further, therapies that are clinically effective in treating acute GVHD are much less effective for chronic GVHD. Together, this suggests that both unique biomarkers and pathophysiologic mechanisms may be involved in chronic GVHD.
Candidate biomarkers may be identified from their correlations with certain chronic GVHD phenotypes. While some correlations might not reflect the underlying pathology, others will suggest new pathophysiologic pathways and potential therapeutic targets. Alternatively, potential biomarkers may be identified via biological hypotheses generated from pre-clinical or theoretical models of chronic GVHD pathophysiology. However, a biomarker does not necessarily directly represent an effector mechanism of chronic GVHD but may reflect a counter-response to control GVHD, or result from nonspecific inflammation or damage.
Purpose of this document
The purpose of this document is to facilitate the identification, verification, qualification and application of chronic GVHD biomarkers. In this document we discuss: a) a standardized nomenclature for biomarkers usage, b) a core set of potentially confounding factors that must be considered when measuring different types of chronic GVHD biomarkers, c) critical concepts and a recommended decision process specific to the selection and development of biomarkers in chronic GVHD, and d) considerations for a repository with the minimal essential clinical data to be provided with each sample.
Summary of 2014 changes
This document replaces the 2005 report [4] of the Biomarker Working Group of the NIH Consensus Development Project on Criteria for Clinical Trials in chronic GVHD.
SUMMARY OF RECOMMENDATIONS
The Biomarker Working Group makes the following recommendations:
1. Biomarker(s) of chronic GVHD should include all of the following components whenever possible:
a. Marker should be identified as diagnostic, prognostic, or predictive of the potential to respond to a treatment, or correlate with response to a treatment that will lead to an important clinical outcome (see Table 1 ).
b. Use of rigorous methodology for measuring the biomarker.
c. Confirmation in at least 2 independent cohorts, each having sufficient power for statistical significance for a clinically relevant hypothesis.
This rigor is required because the observation of a significant association in a single data set does not ensure that the findings can be generalized to other data sets or that the association is specific for the investigated condition. A biomarker confirmed to have a strong association with the investigated condition in at least two independent cohorts would support its use in chronic GVHD clinical trials or patient management. To identify such biomarkers, a coordinated approach to the identification, verification, qualification, and application of biomarkers should be implemented. Prior to clinical application, a higher degree of confidence may be required, such as confirmation of results by an independent group in a different environment and clinical setting.
2.
Both hypothesis-driven studies and discovery-based approaches for identification of chronic GVHD biomarkers are likely to be successful in different circumstances.
3.
Ideally, both chronic GVHD observational prospective studies and chronic GVHD clinical therapeutic trials should include correlative biological studies to allow the identification, verification, qualification and application of biomarkers whenever possible. The main advantages of observational prospective studies are: (1) the study population can be more heterogeneous and representative of the entire population; (2) generally longer longitudinal follow-up than clinical trials; and (3) more patients can be studied. Clinical trials have the advantages that: (1) the study population is often more homogeneous; (2) treatment is controlled; (3) clear outcome assessment; and (4) if randomized, potential sources of bias are minimized.
4.
Samples from well-documented cases and controls should be stored using standardized protocols as proposed in this consensus paper, in order to create a resource for future biomarker studies. Samples types to be collected on cases and controls and minimal essential clinical data to be provided with each sample are detailed below.
DEFINITIONS OF BIOMARKERS AND THEIR APPLICATIONS
A biomarker has been defined by the NIH Biomarker Working Group as a characteristic that is objectively measured as an indicator of normal biological or pathogenic processes, or biological and clinical responses to a therapeutic intervention [5] . The Institute of Medicine has further defined "objectively" to mean "reliably and accurately" [6] . The term "biomarker" commonly refers to a biochemical variable (circulating protein or other biomolecule). Therefore, for the purposes of this document, certain evaluations that are routinely performed to determine the diagnosis of chronic GVHD or to assess the clinical severity of the disease are not discussed but may be considered as biomarkers in certain circumstances. Examples of such evaluations include pulmonary function testing, liver function testing, and radiographic assessment including computed tomography scans.
Biomarkers can be separated into distinct categories of diagnostic, prognostic, and predictive (including response biomarkers), as described in Biomarkers that could be used to predict response to treatment, measure disease activity or distinguish reversible disease activity from irreversible damage would have very high clinical utility, since currently available clinical tools are not adequate for these purposes. In addition, biomarkers that are prognostic for the risk of developing severe chronic GVHD would also have high utility and could be used in pre-emptive trials.
Predictive biomarker studies will have to be annotated not only with demographic and GVHD-related data available at the time of collection, but also with GVHD data relevant to future outcomes. Ideally, samples stored in biorepositories will have outcome data as well, but many times are not set up this way. The CIBMTR TED forms have a lower level of detail regarding chronic GVHD than may be required for some predictive biomarker evaluations. If possible, samples should be de-identified to the repository, and the donating center should retain the identification links. When biomarker studies are performed, investigators could then contact the centers that donated the sample in order to update the data.
RISK FACTORS AND COVARIATES TO CONSIDER
While a biomarker may provide valuable assessment of chronic GVHD, other contributing, confounding conditions must also be considered. Some potential confounding factors are defined below and summarized in Table 2 .
Factors affecting biomarkers directly and independent of onset of chronic GVHD
The conditions of a) immune reconstitution, b) concomitant acute GVHD, c) the type and intensity of current immunosuppressive therapy, d) presence of infections, and e) sample processing and storage, may all affect expression of a chronic GVHD biomarker or its measurement and interpretation. In particular, the analysis of immune-related biomarker data must also account for time from transplant, since immune reconstitution occurs gradually. Organ involvement by chronic GVHD (types of tissues involved and NIH score) and the clinical presentation at onset reflect the chronic GVHD diagnostic phenotype, which may directly affect biomarker levels. Because of the heterogeneity and varied frequency of the clinical syndromes of chronic GVHD, it is unlikely that any given biomarkers will be applicable to all forms or presentations of this disorder.
Covariates and potential confounding factors
A variety of confounding factors may limit the ability to interpret results of chronic GVHD biomarker studies. Each of the following confounding factors may limit the scope and application of a particular biomarker or at least must be controlled for as possible confounding factors in any analysis: a) recipient characteristics such as age; b) donor characteristics including treatment of the donor with G-CSF or other agent (e.g., plerixafor) and graft manipulation (e.g., an HLA-haploidentical graft with T cell depletion or with administration of cyclophosphamide after transplantation); c) donor source (related versus unrelated) and the type of graft (peripheral blood, bone marrow, or umbilical cord blood); and d) recipient preparative conditioning regimen.
Donor versus Recipient Chimerism Criteria for evaluation of chronic GVHD Biomarkers
Significant recipient chimerism is associated with a higher frequency of donor tolerance [9, 10] and could affect the interpretation of chronic GVHD biomarkers when donor-derived hematopoiesis is not fully engrafted. In patients with questionable engraftment, chimerism should be examined, and the patient should be excluded from biomarker studies if results show < 90% donor chimerism, ideally in either lymphoid or myeloid populations.
CRITICAL FRAMEWORK FOR BIOMARKER STUDIES IN CHRONIC GVHD
So far, most potential chronic GVHD biomarkers have been identified based on evaluation at a single center or single laboratory, and have not been through all the steps of verification and qualification necessary to be approved for use in clinical trials, as discussed below and shown in Figure 1 . Only a few studies have included patients derived from multiple centers or independent cohorts of patients. Thus, we propose a four-part framework for the development of chronic GVHD biomarkers ( Figure 1 ). These recommendations are based on guidance for biomarker development from the Institute of Medicine [6] and the US Food and Drug Administration (FDA) in the Center for Drug Evaluation and Research (CDER) [11] . The HCT community will be able to move forward and translate biomarkers into the clinic only if these recommendations are carefully applied in order to avoid previous mistakes, such as 1) strong reliance on convenience samples rather than a prospectively defined population from which specimens are to be collected, 2) absence of a verification cohort that is independent of the discovery cohort, 3) improper statistical methods, for example, when deriving a multiple factor risk score, and 4) failure to consider commonly available clinical information before deducing the additive value of biomarkers. Avoidance of these mistakes will allow our HCT community to move forward in translating biomarkers into the clinic [12, 13] . We have used the new recommended terminology in the headers below [5, 6] to avoid the term "validation", whose different meanings have led to confusion. In Figure 1 we propose a workflow for biomarker discovery. Each step is explained below.
Step 1: Identification
The initial step is the identification of candidate biomarkers in a small experiment of wellmatched cases and controls selected from the populations in which the biomarker is intended for use. At this initial step, it is important to define the clinical context of use and the clinician reported outcome (CRO) or patient reported outcome (PRO) data that will be captured to assess a clinical endpoint, for example, nonrelapse mortality (NRM) or relapse mortality (RM) or more chronic GVHD-specific scales such as the NIH chronic GVHD 0-3 organ score and the Lee chronic GVHD symptom scale. The most appropriate controls for the cases should be defined at this point. It should not be assumed that the same controls are appropriate for different clinical contexts. Factors that should be considered in the choice of controls are discussed in Table 2 .
Step 2: Verification
This step confirms the analytical validity of a test. This includes, among other aspects, the test's reproducibility and accuracy (% coefficient of variation, precision). Test practicality should also be considered: is the potential sample to be measured easy to obtain, is the sample stable until the test can be performed, and is it cost-effective? Of note, before the qualification step, parameters such as cutoff values and sample collection procedures are locked down (finalized) and cannot be changed without re-verification of the test under the revised conditions.
Step 3: Qualification
This step assesses the robustness of the test in all samples from the intended use population for a certain clinical outcome/CRO or PRO (i.e. correctness). Statistical considerations for this step are shown in Table 3 . Other statistical analyses that have been proposed to estimate the performance of biomarkers are reviewed by Pepe et al. [14] . The qualification cohort for step 3 should be entirely distinct and separate from the identification cohort previously studied in step 1, including different center(s) and different demographics, so long as they are consistent with the intended use population. If, however, the demographics are too different from the population for which the biomarker's use is intended, qualification testing could fail inappropriately.
Step 4: Application
In this final step, the biomarker is used in the clinic (e.g. to test all patients suspected of having chronic GVHD) or in a prospective randomized clinical trial, to test the potential to foretell the outcome. If the biomarker successfully qualified, the application step may test: (i) practicality of use in a consortium study, (ii) replacement of a clinical scoring system or invasive biopsies by a simple blood test, (iii) usefulness as an early surrogate indicator of response when testing a new drug as compared to the standard of care. Application testing may require Institutional Review Board (IRB) approval as well as Investigational Device Exemption (IDE) or Investigational New Drug (IND) approval, if clinical management of patients in the study is based on the outcome of the test.
ENSURING ADEQUATE PATIENT CONSENT FOR CHRONIC GVHD BIOMARKER STUDIES
To allow chronic GVHD biomarkers studies, consenting at the time of sample collection is essential. Obtaining consent for both current and future research studies can be accomplished most easily by the appropriate provision at the time of enrollment, in advance of any sample collection followed by de-identifying the sample and providing the correlative clinical data. To obtain consent that allows for a broad variety of clinical studies and sharing with other investigators, a graded level of consent may need to be obtained in the initial consenting process, clarifying whether the participant will allow a) studies on the sample as per the currently outlined studies, b) storage for future studies in chronic GVHD, and c) storage for future studies that may involve disorders other than chronic GVHD. Due to societal sensitivities around "genetic testing" and the common requirement for deposition of genetic information into public databases, specialized consent should be obtained for genebased studies. The consent process should strive to allow for testing or research exchange of coded samples, a process that protects the identity of the subjects but allows access to necessary clinical data through the original provider. A model consent form is attached in supplementary material.
SAMPLE REPOSITORY FOR INVESTIGATION OF CHRONIC GVHD

BIOMARKERS
The largest barrier to new chronic GVHD biomarker development is the lack of good quality biological samples linked to detailed clinical data. Well-conducted large multicenter observation or interventional clinical trials represent excellent formats to provide the consistency of standardized documentation needed to support qualification studies correlating biomarkers with clinical endpoints of interest. However, single institution or observational studies with limited institutional participation in which standardized diagnostic criteria are employed may be sufficient for initial identification studies.
These sample repositories not only would support the exchange of chronic GVHD patient materials for verification of currently proposed biomarkers, but also provide a resource for biomarker discovery through implementation of new technologies. Multiple new technologies are becoming available for analysis of biological fluids, including serum, plasma, saliva, bronchoalveolar lavage fluid and urine). The proteome and metabolome [15, 16] can be analyzed by multiplex ELISA [17] , and peptide arrays to identify autoantibody epitopes [18] . Preserving leukocytes supports future characterization of populations with flow cytometric analyses using as many as 20 fluorochrome channels or 40 channels with mass cytometry (CyTOF) [19] . Preserving cells also supports cell type-specific sorting for molecular analyses. Multiparameter cell characterization can also be done with paraffin embedded pathology specimens by fluorescent immunohistochemistry with imaging through confocal microscopes and multispectral fluorescent imaging analysis supported by quantitative analysis software [20] . RNA and DNA can be recovered from preserved leukocytes, snap-frozen tissue biopsies, from paraffin sections, or even from specific tissue areas in sections through laser capture microdissection [21] . Analyses of RNA and miRNA transcriptomes have been used to characterize gene expression patterns in autoimmunity and inflammation [22, 23] . New bead arrays permit mapping of epigenetic DNA hypomethylation to specific gene loci [24] . Verification of identified genes individually by quantitative RT-PCR is being replaced by platforms utilizing direct multiplexed measurement with RNA and miRNA probe sets, incorporating hundreds of genes to identify multigene patterns [25] . High throughput exome sequencing can identify relevant gene polymorphisms in donors and recipients more rapidly and at lower cost than whole genome approaches, while RNAseq can identify both expression and altered sequences in expressed transcripts in sorted, well-defined cell subsets. Key to the integration of data from these methodologies is the rapidly maturing development of powerful tools for analysis and interpretation of results.
When future biomarker studies are designed, we propose the following considerations. The proposed collection and banking of specimens and data can be very expensive and will require support from research funding sources.
1.
Prospective multicenter studies with collection and banking of samples with an accompanying patient data link, in a manner that complies with regulations for disclosure of protected health information of the country in which the trial is being performed. Assessors will require adequate training to collect the clinical data correctly. The chronic GVHD-focused clinical variables of interest are outlined in the companion NIH Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD Working Group reports. Table 4 presents the minimal recommended data elements that should be linked with each stored sample.
2. Sample acquisition protocols should incorporate both calendar-driven time points and event-driven sample collection. Examples of event-driven sample collection include the point when the patient is first diagnosed with chronic GVHD (or within 2 months) or before start of systemic treatment or at the time of change in treatment. Thus, in the presence of chronic GVHD, we recommend that samples should be obtained within 2 months of onset or treatment change. Since the immune environment changes with post-transplant immune reconstitution, timematched samples should also be obtained from patients who do not have chronic GVHD to serve as controls. In the absence of chronic GVHD, we recommend that samples should be obtained at 3, 6, and 12 months, with additional sampling considered at 9 months, and 18-24 months after transplantation. Ideally, additional samples should be collected yearly, if possible for 6-8 years especially if studies on long term changes associated with established cGVHD are being considered. This schedule will adequately provide samples during the period of greatest risk for development of chronic GVHD and will also allow long-term studies after chronic GVHD treatment.
3.
A centralized repository at the National Marrow Donor Program (NMDP) or possibly a virtual repository with multiple sites collecting in a standardized manner should be established. In the BMT CTN 1201 trial on acute GVHD, shipping of blood up to day +100 has provided materials for processing in a central site. Collection directly into EDTA, Cytochex and Paxgene tubes has provided material for studies of plasma antibodies and stable cytokines, flow cytometric phenotyping of lymphocytes and preservation of RNA for molecular analyses. This powerful approach avoids the need to have specialized local facilities for processing and preservation and standardizes processing and assays to ensure consistent results [26] [27] [28] . However, this approach is limited in three ways. First, plasma cytokines and chemokines are sensitive to both the choice of anticoagulant and the time interval from collection to processing and storage [27, 29] . At individual sites with dedicated core facilities, rapid separation and freezing of serum and plasma (both heparin and EDTA) are recommended for better preservation of cytokines and chemokines. Storing multiple small aliquots (0.5 -1 mL/vial for plasma/serum and 2 × 10 6 for phenotyping studies and 5 × 10 6 cells for functional studies per vial with ideally 5 vials for each patient and time point) avoids refreezing. The volume of blood or tissue collected must be compliant with IRB maximum criteria. Unusual methods to obtain cells, such as leukapheresis, must be considered carefully regarding the risks to the subject. Collection in multiple anticoagulants is preferred, since anticoagulant choice affects measured ELISA cytokine levels and may limit metabolome recovery [27, [30] [31] [32] . Second, storing blood cells for later analysis -particularly in numbers adequate for flow cytometry (at least 5 × 10 6 cells) has the advantage of preserving valuable patient materials for flow cytometric, molecular and functional assays using rapidly developing new technologies. Finally, the calendar-driven sample approach is inflexible in timing and limited in scope of tissues examined. Collection of event-driven samples, such as on the day of diagnosis or of new organ involvement, may be critical to identifying transient biomarkers. Chronic GVHD is pleomorphic; biopsies of chronic GVHD target organs (skin, intestine, liver, and mucosa) or collection of local biofluids such as saliva or bronchial lavage fluid, can be more informative about infiltrating cells and local chemokines than systemic measurements of blood. Formalin-fixed, paraffin embedded diagnostic biopsies of chronic GVHD-affected tissues can be analyzed in more detail with multiparameter immunohistochemistry or serve as a source of securely preserved RNA and microRNA for multiplex RNA analyses [33, 34] . Even if resources to collect these sample types are not available at all sites, dedicated large cores/clinical centers should continue to collect and bank these quality samples locally or with the intent to ship cryopreserved materials to centralized repositories, as in the Chronic GVHD Consortium trials. 
4.
CANDIDATE BIOMARKERS IN CHRONIC GVHD
Potential chronic GVHD biomarkers have been evaluated in both hypothesis-driven and discovery-based testing for specific clinical applications. The data have come primarily from single centers or from a number of collaborating centers; in most cases, the findings have not been assessed as part of large multicenter trials. Despite promising prior investigation, few potential biomarkers have been verified in independent large cohorts of patients as recommended by this consensus document [38] . In Table 5 we present published candidate chronic GVHD biomarkers, organized by application (diagnostic, prognostic, risk stratification, predictive), and then in ascending strata based on the strength of the published evidence. This table illustrates how very few biomarkers have been identified from studies incorporating discovery and independent verification. In addition, studies of chronic GVHD therapeutic response are lacking. Among potential biomarker applications, we emphasize prognostic, risk stratification and predictive biomarkers as major priorities for future investigation. As a reminder, biomarkers are observational correlations and might not necessarily reflect the underlying chronic GVHD pathology. However, they often do, and the biology of the markers listed in Table 5 will be discussed elsewhere.
In conclusion, although progress has been made, much work will be required to verify and qualify the candidate biomarkers identified in previous studies, and to implement highthroughput methods with appropriately collected specimens for future discovery-based approaches. Close coordination between multi-specialty clinical and laboratory-based groups, as well as regulatory agencies and industry partners, will be needed to pursue such studies successfully. We are confident that identification, verification and qualification of biomarkers will greatly assist the development and evaluation of new approaches for treating chronic GVHD.
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an appropriate reference microRNA for diffuse large B-cell lymphoma studies. Table 2 Factors that must be considered for chronic GVHD studies Current infection • Active infections may change cytokine milieu and markers.
• CMV reactivation, pulmonary infections. These considerations apply both during the identification and verification of a biomarker as well as during its subsequent application.
Covariates and potential confounding factors
Recipient characteristics • Younger age associated with lower incidence of chronic GVHD
• Non-malignant diagnoses may affect the incidence and type of chronic GVHD (particularly non-malignant disorders with marrow failure and chromosomal instability appear to have a higher rate of chronic GVHD).
• Allo immunized patients may have a lower rate of engraftment resulting in split donor chimerism and affecting the incidence of chronic GVHD
• Non-HLA polymorphisms may impact incidence or presentation (i.e., ABO incompatibility)
• Biomarkers may be organ specific Table 3 Statistical considerations
A. Analytical performance parameters
• Precision (repeatability and reproducibility of an assay)
• Accuracy
•
Assay sensitivity (limit of detection)
• Assay specificity (interference, cross-reactivity)
• Sample type and matrix
Sample preparation
B. Diagnostic accuracy
• Sensitivity: Proportion of subjects in a sample of patients with the target condition in whom the test is positive.
• Specificity: Proportion of subjects in a sample of patients without the target condition in whom the test is negative.
• Receiver operator characteristic (ROC): A plot of the true-positive rate versus the false-positive rate for all possible thresholds of a biomarker.
• Positive predictive value (PPV): Proportion of patients in the overall population with a positive test who have the target condition.
• Negative predictive value (NPV): Proportion of patients in the overall population with a negative test who do not have the target condition.
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Essential data
Recommended data (will be marker specific) * 
1)
Prior acute GVHD
2)
MAC vs. RIC
3)
Prior chronic GVHD
4)
TCD vs. Not TCD
5)
PBSC vs. BM vs. UCB
6)
Recent B cell depletion
7)
Sex mismatch
8)
HLA mismatch
9)
Active uncontrolled infection (particularly CMV)
10)
Age of the patient and recipient
11)
WBC and ALC Although suggested they are not routinely captured at most centers
12)
Prior Immunosuppressive therapies failed
13)
Absolute T and B cells counts
14)
IgG levels * Variables that could confound the analyses ( 
